Novo Nordisk Collaborates with Dicerna to Discover and Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases

 Novo Nordisk Collaborates with Dicerna to Discover and Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases

Novo Nordisk Collaborates with Dicerna to Discover and Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases

Shots:

  • Dicerna to receive $175M up front, $50M equity investment, $75M for first three years of collaboration and up to $375.5M/ target as development, regulatory and commercialization milestones with royalties on product sales
  • Both the companies will retain rights to co-develop and co-commercialize candidates and will explore up to 30 liver cell targets for which Dicerna will be responsible to conduct & fund discovery & preclinical development into clinical for each target while Novo Nordisk to be responsible for all further developments
  • The collaboration allows Novo Nordisk to access Dicerna’s GalXC RNAi platform for delivering clinical candidates targeting chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity, and rare diseases

Click here to­ read full press release/ article | Ref: Novo Nordisk | Image: Finans

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post